Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(112)
•••
Post by MBT123on Dec 11, 2020 3:09pm
146 Views
Post# 32090182

Part-Time CEO=.20 Stock

Part-Time CEO=.20 StockWell our part-time CEO must have gotten bored trying to get any deals with any amount of money upfront and mailed it in..Seems as tho the technology isn't anything close to what's touted on here by JD and crew..Now there gonna sit around and wait for a "partner" they just realized this now after years of saying many deals were imminent! It's blantaly obvious the technology and time frame to move this forward has major holes..Our 3rd CEO just like ones prior hasn't gotten any traction..She signed a couple deals with barely enough money too keep the lights on and pay JD that got zero ziltch nada of the markets attention...Let's just keep saying our technology is better than a 9b company as we wither away too pennies just like she did in the past..The behind the scenes holes in this technology is very apparent in our dwindling SP and half-assed committed CEO..Well maybe a big pharma will stumble upon JDs new website and only then realize how special this really is, that's when this will take off..
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities